Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling
Zhaojie Meng, Taesik Gwag, Yipeng Sui, Se-Hyung Park, Xiangping Zhou, Changcheng Zhou
Zhaojie Meng, Taesik Gwag, Yipeng Sui, Se-Hyung Park, Xiangping Zhou, Changcheng Zhou
View: Text | PDF
Research Article Endocrinology Metabolism

The atypical antipsychotic quetiapine induces hyperlipidemia by activating intestinal PXR signaling

  • Text
  • PDF
Abstract

Quetiapine, one of the most prescribed atypical antipsychotics, has been associated with hyperlipidemia and an increased risk for cardiovascular disease in patients, but the underlying mechanisms remain unknown. Here, we identified quetiapine as a potent and selective agonist for pregnane X receptor (PXR), a key nuclear receptor that regulates xenobiotic metabolism in the liver and intestine. Recent studies have indicated that PXR also plays an important role in lipid homeostasis. We generated potentially novel tissue-specific PXR-KO mice and demonstrated that quetiapine induced hyperlipidemia by activating intestinal PXR signaling. Quetiapine-mediated PXR activation stimulated the intestinal expression of cholesterol transporter Niemann-Pick C1-Like 1 (NPC1L1) and microsomal triglyceride transfer protein (MTP), leading to increased intestinal lipid absorption. While NPC1L1 is a known PXR target gene, we identified a DR-1–type PXR-response element in the MTP promoter and established MTP as a potentially novel transcriptional target of PXR. Quetiapine’s effects on PXR-mediated gene expression and cholesterol uptake were also confirmed in cultured murine enteroids and human intestinal cells. Our findings suggest a potential role of PXR in mediating adverse effects of quetiapine in humans and provide mechanistic insights for certain atypical antipsychotic-associated dyslipidemia.

Authors

Zhaojie Meng, Taesik Gwag, Yipeng Sui, Se-Hyung Park, Xiangping Zhou, Changcheng Zhou

×

Figure 1

The atypical antipsychotic quetiapine is a PXR-selective agonist.

Options: View larger image (or click on image) Download as PowerPoint
The atypical antipsychotic quetiapine is a PXR-selective agonist.
(A and...
(A and B) HepG2 cells were transfected with (A) full-length hPXR together with hPXR reporter (CYP3A4-luc) or (B) full-length mPXR together with mPXR reporter ([CYP3A2]3-luc) and CMX–β-galactosidase control plasmids. Cells were then treated with DMSO control, quetiapine, aripiprazole, and rifampicin (hPXR ligand) or pregnenolone 16α-carbonitrile (mPXR ligand) at the indicated concentrations for 24 hours (n = 3, 1-way ANOVA, *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control group). (C and D) HepG2 cells were transfected with hPXR and CYP3A4-luc reporter (C) or mPXR and (CYP3A2)3-luc reporter (D) together with CMX–β-galactosidase plasmids. Cells were then treated with quetiapine or aripiprazole at the indicated concentrations for 24 hours (n = 3). (E) HepG2 cells were transfected with a GAL4 reporter and a series of GAL4 plasmids in which the GAL4 DNA-binding domain is linked to the indicated nuclear receptor ligand–binding domain. Cells were treated with DMSO control or 20 μM quetiapine for 24 hours (n = 3, Student’s t test, **P < 0.01, ***P < 0.001 compared with control group).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts